What's Wrong With Vertex Pharmaceuticals Stock?
Vertex Pharmaceuticals (NASDAQ: VRTX) has been a top pharma stock in recent years. It has been generating strong revenue growth while also building out its portfolio of drugs, expanding its growth opportunities in the process. This is the type of stock that you might expect to see taking off this year.
But that isn't happening.
Instead, the share price of Vertex recently plunged. Excitement around the company has cooled drastically. What's wrong with Vertex Pharmaceuticals, and is it an investment worth buying on the dip, or could there be more trouble ahead for the healthcare stock?
Source Fool.com
Vertex Pharmaceuticals Inc. Aktie
340,10 €
1,37 %
Vertex Pharmaceuticals Inc. als klarer Gewinner: Nur Buy-Einschätzungen, keine Sell-Einschätzungen.
Das Kursziel von 476 € für Vertex Pharmaceuticals Inc. weist auf eine Steigerung von über 20% gegenüber dem aktuellen Kurs von 340.1 € hin.
